http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110872341-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate | 2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110872341-B |
| titleOfInvention | FGFR 1-targeted antagonistic short peptide |
| abstract | The invention belongs to the field of short peptide pharmacology, particularly relates to stability research of FGFR1 antagonistic short peptide and application of the antagonistic short peptide in the field of anti-tumor, and discloses FGFR1 antagonistic short peptide which comprises a short peptide compound P48, wherein the short peptide compound P48 inhibits cell proliferation and migration by inhibiting an FGFR1 channel. The present inventors have diligently made efforts to obtain the short peptide compound P48, and found that it has a stable secondary structure and a relatively long half-life. In addition, the short peptide compound P48 can effectively inhibit FGFR1 in a targeted mode, shows good antitumor activity in vivo and in vitro, and is expected to become a candidate peptide inhibitor drug for cancer treatment. |
| priorityDate | 2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.